Frank Walsh | Chief Executive Officer
Ossianix, Inc.

Frank Walsh is the founder and CEO of Ossianix a privately held Biotechnology company that focuses on single domain VNAR antibodies with with a major interest in brain shuttles for Neurodegenerative diseases Formerly, Frank was head of Discovery Research worldwide at Wyeth Pharmaceuticals in Collegeville, PA (2002-2009).  Prior to joining Wyeth, he was SVP at GlaxoSmithKline UK and Head of the Neurology CEDD from 2000.  From 1997-2000 he was VP of Neuroscience Research at Smith Kline Beecham UK.  Before joining the pharmaceutical industry, Frank had a distinguished academic career in Neuroscience as the Sir William Dunn Professor of Experimental Pathology at London’s UMDS, Guy’s Hospital. He is the author of over 200 scientific publications and is a Fellow of the Royal Society of Edinburgh and the UK Academy of Medical Sciences.